Selective androgen receptor modulators and methods of use...

Details Selective androgen receptor modulators and methods of use... Selective androgen receptor modulators and methods of use...

2005-06-07

2009-11-24

Kumar, Shailendra (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S524000, C514S619000

Reexamination Certificate

active

07622503

ABSTRACT:
This invention provides SARM compounds and their use in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

REFERENCES:
patent: 3239345 (1966-03-01), Hodge et al.
patent: 3865801 (1975-02-01), Chiba et al.
patent: 3875229 (1975-04-01), Gold
patent: 4036979 (1977-07-01), Asato
patent: 4139638 (1979-02-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4239776 (1980-12-01), Glen et al.
patent: 4282218 (1981-08-01), Glen et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4411890 (1983-10-01), Momany et al.
patent: 4465507 (1984-08-01), Konno et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4880839 (1989-11-01), Tucker
patent: 4977288 (1990-12-01), Kassis et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5179080 (1993-01-01), Rothkopf et al.
patent: 5441868 (1995-08-01), Lin et al.
patent: 5547933 (1996-08-01), Lin et al.
patent: 5609849 (1997-03-01), Kung
patent: 5612359 (1997-03-01), Murugesan et al.
patent: 5618698 (1997-04-01), Lin et al.
patent: 5621080 (1997-04-01), Lin et al.
patent: 5656651 (1997-08-01), Sovak et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6071957 (2000-06-01), Miller et al.
patent: 6160011 (2000-12-01), Miller et al.
patent: 6482861 (2002-11-01), Miller et al.
patent: 6492554 (2002-12-01), Dalton et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6777427 (2004-08-01), Miyakawa et al.
patent: 6838484 (2005-01-01), Steiner et al.
patent: 6899888 (2005-05-01), Steiner et al.
patent: 6960474 (2005-11-01), Salvati et al.
patent: 6995284 (2006-02-01), Dalton et al.
patent: 6998500 (2006-02-01), Dalton et al.
patent: 7026500 (2006-04-01), Dalton et al.
patent: 7041844 (2006-05-01), Miller et al.
patent: 7344700 (2008-03-01), Dalton et al.
patent: 2001/0012839 (2001-08-01), Miller et al.
patent: 2002/0173445 (2002-11-01), Salvati et al.
patent: 2003/0232792 (2003-12-01), Dalton et al.
patent: 2004/0014975 (2004-01-01), Dalton et al.
patent: 2004/0029913 (2004-02-01), Dalton et al.
patent: 2004/0053897 (2004-03-01), Steiner et al.
patent: 2004/0087557 (2004-05-01), Steiner et al.
patent: 2004/0087810 (2004-05-01), Dalton et al.
patent: 2004/0147489 (2004-07-01), Dalton et al.
patent: 2004/0260092 (2004-12-01), Miller et al.
patent: 2005/0137172 (2005-06-01), Dalton et al.
patent: 2006/0183931 (2006-08-01), Dalton et al.
patent: 2007/0066568 (2007-03-01), Dalton et al.
patent: 2007/0123563 (2007-05-01), Dalton et al.
patent: 2007/0173546 (2007-07-01), Dalton et al.
patent: 2002364949 (2003-06-01), None
patent: 2003216174 (2003-09-01), None
patent: 2420279 (2002-02-01), None
patent: 2477737 (2003-09-01), None
patent: 2502209 (2004-04-01), None
patent: 2502355 (2004-04-01), None
patent: 2538095 (2004-04-01), None
patent: 25029464 (2005-06-01), None
patent: 0 040 932 (1981-02-01), None
patent: 0 100 172 (1984-02-01), None
patent: 00 02 892 (1985-02-01), None
patent: 000 2892 (1985-02-01), None
patent: 0253 503 (1991-12-01), None
patent: 0253503 (1991-12-01), None
patent: 668351 (1995-08-01), None
patent: 1221439 (2002-07-01), None
patent: 1401801 (2006-11-01), None
patent: 1801140 (2007-06-01), None
patent: 1360001 (1970-03-01), None
patent: 52-128329 (1977-10-01), None
patent: 54-63047 (1980-12-01), None
patent: 59-033250 (1984-02-01), None
patent: WO 98/07110 (1989-08-01), None
patent: WO 98/07111 (1989-08-01), None
patent: WO 91/05867 (1991-05-01), None
patent: WO 93/04081 (1993-03-01), None
patent: WO 95/19770 (1995-07-01), None
patent: WO 98/05962 (1998-02-01), None
patent: WO 98 05962 (1998-02-01), None
patent: WO 98/53826 (1998-12-01), None
patent: WO 98/55153 (1998-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO/01/27086 (2001-04-01), None
patent: WO 01/27086 (2001-04-01), None
patent: WO 01 27622 (2001-04-01), None
patent: WO 01/27622 (2001-04-01), None
patent: WO 01/28990 (2001-04-01), None
patent: WO 01 28990 (2001-04-01), None
patent: WO 01/34563 (2001-05-01), None
patent: WO 01 34563 (2001-05-01), None
patent: WO 01/68603 (2001-09-01), None
patent: WO 02 00617 (2002-01-01), None
patent: WO 02/00617 (2002-02-01), None
patent: WO 02/016310 (2002-02-01), None
patent: WO 02/16310 (2002-02-01), None
patent: WO/02/22585 (2002-03-01), None
patent: WO 02/22585 (2002-03-01), None
patent: WO 03/011302 (2003-02-01), None
patent: WO 03/049675 (2003-06-01), None
patent: WO 03/065992 (2003-08-01), None
patent: WO 03/074449 (2003-09-01), None
patent: WO 03/077919 (2003-09-01), None
patent: WO/03/077919 (2003-09-01), None
patent: WO 2004/035736 (2004-04-01), None
patent: WO 2005/000794 (2005-01-01), None
patent: WO 2005/060647 (2005-07-01), None
U.S. Appl. No. 09/935,044, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/935,045, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/644,970, filed Aug. 2, 2000, Dalton et al.
Eliason et al., “High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands,” Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, (2002), Apr. 7, 2002 .
Berger et al., “Concepts and limitations in the application of radiolabeled antiandrogens, estrogens, or androgens as isotropic scanning agents for the prostate”, Invest. Urol, (1975), 1391, 10-16.
Howard Tucker and Glynne J. Chesterson, J. Med Chem. 1988, 31, pp. 885-887, “Resolution of the Nonsteroidal Antiandrogen -4'-Cyano-3-[(4-fluorophenyl)sulfony1]-2-hydroxy-2-methyl-3'-(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer”.
D. McKillop, et al, “Enantioselective metabolism and pharmacokinetics of Casodex in the male rat”, Xenobiotica, 1995, vol. 25, No. 6, 623-634.
Leonid Kirkovsky, et al., “[125I]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer”, Poster Presentation MEDI 155, 214th ACS National Meeting, Las Vegas, NV, Sep. 7-11, 1997, Deparment of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163.
David T. Baird and Anna F. Glasier, “Hormonal Contraception—Drug Therapy”, the New England Journal of Medicine, May 27, 1993, pp. 1543-1549.
F.C. W. Wu, “Male Contraception: Current Status and Future Prospects”, Clinical Endocrinology, (1988), 29, pp. 443-465.
Carl Djerassi and S.P. Leibo, “A new look at male contraception”, Nature, vol. 370, pp. 11-12.
World Health Organisation Task Force on Methods for the Regulation of Male Fertility, “Contraceptive efficacy of testosterone-induced azoospermia in normal men”, the Lancet, vol. 336, Oct. 20, 1990, pp. 955-959and 1517-1518.
C. G. Francisco, et al., “Long-acting contraceptive agents: testosterone esters of unsaturated acids”, Steroids, Jan. 1990, vol. 55, Butterworths.
John M. Hoberman and Charles E. Yesalis, “The History of Synthetic Testosterone”, Scientific American, Feb. 1995, pp. 76-81.
Leonid Kirkovsky, et al., “Approaches to Irreversible non-steroidal chiral antiandrogens”, Department of Pharmaceutical Sciences, University of Tennessee, 47th Southeast/51st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, Nov. 29-Dec. 1, 1995.
Edwards JP, Higuchi RI, Winn DT, Pooley CLF, Caferro TR, Hamann LG, Zhi L. Marschke KB, Goldman ME, and Jones TK. Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin:2-one. Bioorg. Med. Chem. Lett., 9:1003, 1999.
Zhi L, Tegley CM, Marschke KB, and Jones TK. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 9: 1009. 1999.
Higuchi RI, Edwards JP, Caferro TR, Ringgeriberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, and Jones TK. 4-Alkyl- and 3,4-diaklyl-l,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, no

Affiliated with

Also associated with

Rating

Selective androgen receptor modulators and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective androgen receptor modulators and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective androgen receptor modulators and methods of use... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4097112